Whether you choose semaglutide, tirzepatide, or a compounded blend, the principles of sterile technique, accurate water measurement, gentle mixing, and proper storage apply universally
Who Should Avoid It : See shared GLP-1 CI/precautions above
Wegovy Data as Reported by Novo Nordisk The manufacturers language on the weight loss indication reads thus: Wegovy (semaglutide) injection 2.4 mg is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity and adults with overweight in the presence of at least one weight-related comorbidity. At two years, patients taking Wegovy showed a mean weight loss of 15% or 34 pounds, from a mean baseline BMI of 38.5
What is first-pass metabolism and how does it affect oral BPC-157
Microdosing GLP-1 for Hashimoto's: Evidence, Risks and NHS Guidance Microdosing GLP-1 for Hashimoto's has emerged as a topic of interest amongst patients seeking metabolic support for autoimmune thyroid disease